CUL Stock Overview Aspira Women's Health Inc., together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States. More details
Rewards Risk Analysis + 2 more risks
See All Risk Checks Capture your thoughts, links and company narrative
Aspira Women's Health Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Aspira Women's Health Historical stock prices Current Share Price US$0.31 52 Week High US$4.80 52 Week Low US$0.28 Beta 1.42 1 Month Change -48.00% 3 Month Change -58.12% 1 Year Change -93.39% 3 Year Change -97.81% 5 Year Change -96.99% Change since IPO -99.99%
Recent News & Updates Aspira Women's Health Inc. Appoints James Crawford as Principal Accounting Officer
Aspira Women's Health Inc. Appoints Mike Buhle as SVP of Commercial Operations Jan 10 Aspira Women's Health Inc. has filed a Follow-on Equity Offering. Jan 09
Aspira Women's Health Announces Resignation of John Kallassy as Interim Chief Financial Officer, Effective January 10, 2025 Jan 08
Aspira Women's Health Inc. Provides Nasdaq MVLS Non-Compliance Update Jan 01 Aspira Women's Health Inc. Announces Departure of Nicole Sandford as Board Member See more updates Aspira Women's Health Inc. Appoints James Crawford as Principal Accounting Officer
Aspira Women's Health Inc. Appoints Mike Buhle as SVP of Commercial Operations Jan 10 Aspira Women's Health Inc. has filed a Follow-on Equity Offering. Jan 09
Aspira Women's Health Announces Resignation of John Kallassy as Interim Chief Financial Officer, Effective January 10, 2025 Jan 08
Aspira Women's Health Inc. Provides Nasdaq MVLS Non-Compliance Update Jan 01 Aspira Women's Health Inc. Announces Departure of Nicole Sandford as Board Member
Aspira Women's Health Inc. Successfully Reaches the First Milestone of the Advanced Research Projects Agency for Health $10 Million Award Dec 04 Aspira Women's Health Inc. announced delayed 10-Q filing Nov 15
Aspira Women's Health Inc. to Report Nine Months, 2024 Results on Nov 14, 2024 Nov 04 Aspira Women's Health Inc. Announces Its Selection Receive $10 Million Award from Advanced Research Projects Agency for Health’s Sprint for Women's Health Oct 24
Aspira Women's Health Receives Written Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement Oct 19
Second quarter 2024 earnings released: US$0.28 loss per share (vs US$0.28 loss in 2Q 2023) Aug 13
Aspira Women's Health Inc. Appoints John Kallassy as Interim Chief Financial Officer, Effective August 15, 2024 Aug 13
New major risk - Shareholder dilution Aug 05 Aspira Women's Health Inc. has filed a Follow-on Equity Offering in the amount of $4.45 million. Aug 03
Aspira Women's Health Inc. to Report Q2, 2024 Results on Aug 12, 2024 Aug 01
Aspira Women’s Health Inc Appoints John Ragard to Its Board of Directors Jul 29
New major risk - Shareholder dilution Jul 14 Aspira Women's Health Inc. announced that it has received $1.910249 million in funding Jul 10
Aspira Women’s Health Receives Written Notice from Nasdaq Due to Non-Compliance with the Minimum of $35 Million Market Value of Listed Securities Requirement Pursuant to Nasdaq Listing Rule 5550(b)(2) Jul 06 Aspira Women's Health Inc. announced that it expects to receive $1.935051 million in funding Jul 02
First quarter 2024 earnings released: US$0.39 loss per share (vs US$0.73 loss in 1Q 2023) May 17
Aspira Women's Health Inc. to Report Q1, 2024 Results on May 15, 2024 May 10
Aspira Women's Health Inc. Enhances Its Commercial Offering with the Formal Launch of Longitudinal Monitoring Feature of Ovawatch May 03
Aspira Women's Health Inc. Announces Minh Merchant Resigns as General Counsel, Chief Compliance Officer, and Corporate Secretary, Effective May 6, 2024 Apr 28
Aspira Women's Health Inc., Annual General Meeting, May 13, 2024 Apr 02
Full year 2023 earnings released: US$1.81 loss per share (vs US$3.85 loss in FY 2022) Mar 29
Aspira Women's Health Inc. Announces Executive Changes Mar 20
Aspira Women's Health Inc. to Report Q4, 2023 Results on Mar 28, 2024 Mar 12
High number of new and inexperienced directors Feb 05 Aspira Women's Health Inc. has filed a Follow-on Equity Offering in the amount of $5.50031 million. Jan 26
Aspira Women's Health Inc. Announces Resignation of Veronica G.H. Jordan from the Board of Directors Dec 28
Aspira Women's Health Provides Development Update on its Portfolio of Noninvasive Tests for Endometriosis Dec 06
Aspira Women's Health Receives Final Crosswalk Pricing Determination from the Centers for Medicare & Medicaid Services (CMS) Nov 29
Aspira Women's Health Receives Final Crosswalk Pricing Determination from the Centers for Medicare & Medicaid Services (CMS) Nov 28
Aspira Women's Health Inc. to Report Q3, 2023 Results on Nov 13, 2023 Nov 02
Aspira Women's Health Sees Poster on its MiRNA-Based Ovarian Cancer Test Presented at the AACR Special Conference in Cancer Research Oct 26
Aspira Women's Health Establishes A New Clinical Advisory Board Oct 24
Aspira Women’s Health Regains Nasdaq Compliance Sep 14
Aspira Women’s Health Announces Executive Changes Sep 12
Aspira Women’s Health Announces Michelle Snider as Senior Vice President, Commercial Strategy and Operations Aug 29
Aspira Women’S Health Inc. Announces Resignation of Ryan Phan as Chief Scientific and Operating Officer, Effective September 15, 2023 Aug 10
Aspira Women's Health Inc. to Report Q2, 2023 Results on Aug 14, 2023 Aug 01
Aspira Women’s Health Receives Written Notice from the Listing Qualifications Staff of the Nasdaq Stock Market Jul 16
Aspira Women's Health Inc. Appoints Dr. Winfred Parnell to Its Board of Directors, Member of Nominating and Corporate Governance Committee Jun 07
Aspira Women's Health Inc. Appoints Dr. Winfred Parnell to Its Board of Directors Jun 06
Aspira Women's Health Inc. Announces Chief Financial Officer Changes, Effective June 15, 2023 May 17
First quarter 2023 earnings released: US$0.73 loss per share (vs US$1.24 loss in 1Q 2022) May 13
Aspira Women's Health Inc. Appoints Three New Members to Its Board of Directors May 10
Full year 2022 earnings released: US$0.23 loss per share (vs US$0.28 loss in FY 2021) Mar 24
Aspira Women’s Health Inc. Announces Publication of Real-World Data Validating Use of OvaWatch for Management of Adnexal Masses Jan 07
Aspira Women's Health Inc. Announces Executive Changes Dec 24 Aspira Women's Health Receives A Written Notice from Nasdaq
Aspira Women's Health Inc. Announces the Commercial Launch of OvaWatch Dec 02
Third quarter 2022 earnings released: US$0.039 loss per share (vs US$0.087 loss in 3Q 2021) Nov 16
Third quarter 2022 earnings released: US$0.039 loss per share (vs US$0.087 loss in 3Q 2021) Nov 12
Aspira Women's Health Inc. to Report Q3, 2022 Results on Nov 10, 2022 Nov 02
Aspira Women's Health Inc. Announces Publication of Its Second-Generation Multivariate Index Assay, Overa®, in the Detection of Cancer in Filipino Women Sep 13 Aspira Women's Health Inc. has completed a Follow-on Equity Offering. Aug 24
Second quarter 2022 earnings released: US$0.073 loss per share (vs US$0.063 loss in 2Q 2021) Aug 12
Aspira Women's Health Inc. to Report Q2, 2022 Results on Aug 10, 2022 Aug 02
Aspira Women's Health Inc. Announces Board Appointments Jun 24
Aspira Women’s Health Inc. Receives A Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market Jun 03
President recently bought €72k worth of stock May 19
First quarter 2022 earnings released: US$0.083 loss per share (vs US$0.054 loss in 1Q 2021) May 13
Aspira Women's Health Inc. Appoints Ryan Phan, Ph.D. as Chief Operating and Scientific Officer May 13 Aspira Women's Health Inc., Annual General Meeting, Jun 23, 2022
High number of new directors Mar 29
Aspira Women's Health Inc. Appoints Valerie B. Palmieri as Its Executive Chairperson Mar 03
Aspira Women’S Health Announces Appointment of Celeste Fralick to Its Board of Directors Mar 01 Aspira Women's Health Inc. Appoints Nicole Sandford as Chief Executive Officer, Effective March 1, 2022
Aspira Women’s Health, Inc. Name Mr. Michael Newton as Head of Sales and Marketing Feb 24
Third quarter 2021 earnings released: US$0.087 loss per share (vs US$0.042 loss in 3Q 2020) Nov 11
Second quarter 2021 earnings released: US$0.063 loss per share (vs US$0.039 loss in 2Q 2020) Aug 13 Shareholder Returns CUL DE Medical Equipment DE Market 7D -11.4% 2.9% 1.9% 1Y -93.4% -1.0% 15.1%
See full shareholder returns
Return vs Market: CUL underperformed the German Market which returned 15.1% over the past year.
Price Volatility Is CUL's price volatile compared to industry and market? CUL volatility CUL Average Weekly Movement 16.4% Medical Equipment Industry Average Movement 6.3% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.3% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: CUL's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: CUL's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company Aspira Women's Health Inc., together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States. The company’s products include Ova1Plus, a qualitative serum test to assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker test intended to maintain Ova1’s high sensitivity; and OvaWatch, a laboratory developed tests to assist in the initial clinical assessment of malignancy risk in all women thought to have an indeterminate or benign adnexal mass. It is also developing OvaMDx, a multi-marker test that combines serum proteins, clinical data, and miRNA for assessing the risk of ovarian cancer in women with an adnexal mass; EndoCheck, a protein biomarker designed to identify ovarian endometriomas; and EndoMDx for the identification of endometriosis.
Show more Aspira Women's Health Inc. Fundamentals Summary How do Aspira Women's Health's earnings and revenue compare to its market cap? CUL fundamental statistics Market cap €6.06m Earnings (TTM ) -€14.27m Revenue (TTM ) €8.65m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) CUL income statement (TTM ) Revenue US$8.96m Cost of Revenue US$3.75m Gross Profit US$5.21m Other Expenses US$20.00m Earnings -US$14.79m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -0.89 Gross Margin 58.12% Net Profit Margin -165.07% Debt/Equity Ratio -62.0%
How did CUL perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/02/02 00:29 End of Day Share Price 2025/01/31 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Aspira Women's Health Inc. is covered by 10 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution James Molloy Alliance Global Partners Benjamin Haynor Alliance Global Partners Laura McGuigan B. Riley Securities, Inc.
Show 7 more analysts 
